A voluntary collaboration of EU member states, patients and industry plans to present recommendations this week for a framework to assess the value of Orphan drugs that could be used as the basis for pricing negotiations at the national level.

In principle, the plan seeks to reduce the health technology assessment burden on smaller EU member states and make the reimbursement process more predictable for companies, in turn increasing patient access to Orphan drugs.